BMRN | tickerfilter.com

Fundamental analysis

35%

Profitability 20%

Dept financing 10%

Liquidity 75%

Performance 47%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.38%

1 Month

-10.91%

3 Months

-0.76%

6 Months

-9.91%

1 Year

-23.32%

2 Year

-35.06%

Key data

Stock price

$62.98

P/E Ratio

29.35

DAY RANGE

$62.19 - $63.87

EPS

$2.25

52 WEEK RANGE

$52.93 - $94.85

52 WEEK CHANGE

-$22.02

MARKET CAP

12.527 B

YIELD

N/A

SHARES OUTSTANDING

189.880 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-01-2025

BETA

-0.01

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,847,268

AVERAGE 30 VOLUME

$2,083,257

Company detail

CEO: Jean-Jacques Bienaimé
Region: US
Website: biomarin.com
Employees: 3,080
IPO year: 1999

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

BMRN - BIOMARIN PHARMACEUTICAL INC